# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly hig...
Bristol Myers Squibb (NYSE:BMY) today announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-T...
Jefferies analyst Akash Tewari maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the price target from $49 to...
Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms,...
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomb...
Bristol Myers Squibb (NYSE:BMY) today announced the presentation of research across its robust cardiovascular portfolio at the ...